Precedo Pharmaceuticals Co., Ltd

Chinese Academy of Sciences

Hefei Cosource Pharmaceutical Co., Ltd.

Xixiang Li

Cheng Chen

Jing Liu

Li Wang

Qingsong Liu

Beilei Wang

Wenchao Wang

Chen Hu

Aoli Wang

Ziping Qi

Wei Wang

Hong Wu

Kailin Yu

Jiaxin Wu

Fengming Zou

Juan Liu

Zheng Zhao

The present invention provides a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound of formula (I), as well as the use and method for preventing or treating FLT3-related conditions, especially conditions related to mutant FLT3 kinase (particularly, FLT3/ITD mutant kinase). 

Inhibitor of FLT3 kinase and use thereof

The present application provides a compound of Formula (I) as an inhibitor against wild-type EGFR and/or mutant EGFR, which may be used for treating human non-small cell lung cancer individually or in combination with other therapeutic agent(s). The compound of Formula (I) of the present application may be used for treating patients of drug-resistant human non-small cell lung cancer harboring wild-type EGFR and/or EGFR T790M mutation and/or EGFR L858R mutation and/or EGFR delE746_A750 mutation. 

Kinase inhibitor against wild-type and mutant EGFR

Provided in the present invention is a novel inhibitor of FLT3 kinase, comprising a compound of formula (I) or a pharmaceutically acceptable salt, solvate, isomer, ester, acid, metabolite or prodrug thereof. Also provided in the present invention are a pharmaceutical composition comprising a compound of formula (I) and a use and method for preventing or treating cell proliferative conditions and/or FLT3-related conditions, in particular for conditions responding to the inhibition of FLT3 kinase (especially FLT3/ITD mutant kinases). 

Growing community of inventors

Anhui, China

Xixiang Li